When to Consider Radiation Therapy for Your Patient



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 1999 Mar 1;59(5):1177-1184.

Radiation therapy can be an effective treatment modality for both malignant and benign disease. While radiation can be given as primary treatment, it may also be used pre- or postoperatively, with or without other forms of therapy. Radiation therapy is often curative but is sometimes palliative. There are many methods of delivering radiation effectively. Often, patients tolerate irradiation well without significant complications, and organ function is preserved. To ensure that all patients with cancer have the opportunity to consider all treatment options, family physicians should be aware of the usefulness of radiation therapy.

In the United States, approximately one of every two men and one of every three women will have cancer (including skin cancer).1 Obviously, family physicians play a major role in the care of many of these patients. In this country, approximately 60 percent of all patients with cancer receive radiation therapy each year.2  Unfortunately, physicians sometimes direct cancer treatment without considering the option of radiation therapy. Family physicians should be aware of its potential role (Table 1) in order to ensure that patients receive comprehensive cancer management.

TABLE 1

Comparison of Primary Treatment Modalities for Selected Cancers

Disease site Expectation Radiation (percentage effective)* Surgery (percentage effective)* Chemotherapy

Anal canal

Disease-free survival

70

70

With radiation

Colostomy-free survival

70

0

Bladder

Five-year survival

45

40

With radiation

Bladder T2,T3

Bladder preservation

60

0

Breast

10-year survival

70

70

Breast—stage I, stage II

Breast preservation

90

0

Esophagus

Five-year survival

10

10

With radiation

Head and neck—stage I, stage II

Larynx

Local control

85

85

Oral cavity

Local control

85

85

Oropharynx

Local control

85

85

Hodgkin's disease—stage I, stage II

10-year survival

90

60 to 85 %

Lung—stage III

Five-year survival

10

<5

With radiation

Prostate—stage I, stage II

10-year survival

60

60

Skin, basal cell

Local control

95

95

Skin, squamous cell

Local control

90

90

Uterine cervix—stage IB, stage IIA

Five-year survival

85

85


*—Percentages are approximate.

TABLE 1   Comparison of Primary Treatment Modalities for Selected Cancers

View Table

TABLE 1

Comparison of Primary Treatment Modalities for Selected Cancers

Disease site Expectation Radiation (percentage effective)* Surgery (percentage effective)* Chemotherapy

Anal canal

Disease-free survival

70

70

With radiation

Colostomy-free survival

70

0

Bladder

Five-year survival

45

40

With radiation

Bladder T2,T3

Bladder preservation

60

0

Breast

10-year survival

70

70

Breast—stage I, stage II

Breast preservation

90

0

Esophagus

Five-year survival

10

10

With radiation

Head and neck—stage I, stage II

Larynx

Local control

85

85

Oral cavity

Local control

85

85

Oropharynx

Local control

85

85

Hodgkin's disease—stage I, stage II

10-year survival

90

60 to 85 %

Lung—stage III

Five-year survival

10

<5

With radiation

Prostate—stage I, stage II

10-year survival

60

60

Skin, basal cell

Local control

95

95

Skin, squamous cell

Local control

90

90

Uterine cervix—stage IB, stage IIA

Five-year survival

85

85


*—Percentages are approximate.

Radiation Treatment

MECHANISM OF ACTION

Radiation therapy is a local treatment modality that works by damaging the DNA of malignant cells. Normal cells have a greater ability to repair this damage than tumor cells. Radiation therapy takes advantage of this difference. It is important to note that since damaged cells do not die immediately after treatment, tumors often persist after successful radiation therapy is completed.

APPROACH TO TREATMENT PLANNING

Treatment prescriptions are based on the goals of treatment and the potential for side effects. A course of treatment may be as short as one day or as long as 10 weeks, but a typical duration is between two and seven weeks and usually consists of five daily treatments a week. Patients most commonly receive radiation through a linear accelerator, which accelerates electrons to be used as a treatment beam or to generate x-rays to be used as a treatment beam. Treatment is not painful and often lasts less than five minutes.

The goal of treatment may be curative or palliative. If radiotherapy is potentially curative, the length of treatment is often longer and usually consists of smaller daily doses over a longer period of time. This approach minimizes late side effects. If treatment is intended to be strictly palliative, shorter treatment schedules consisting of larger daily treatment doses over a shorter time period are used. In such cases, late side effects are not likely to occur within the patient's lifetime. Furthermore, a shorter treatment program will negatively affect less of the patient's remaining life.

Side Effects of Radiation Therapy

Since radiation is a form of local therapy, side effects are usually limited to the treated area. However, fatigue is one common systemic symptom. Usually, the side effects of radiation are mild, but occasionally they are severe. The side effects can be divided into early and late effects (Table 2).3 Early effects occur during or immediately after treatment and typically resolve within three to six weeks following therapy. Late side effects occur months to years after treatment and are often permanent. These effects are the result of tissue injury that leads to necrosis or scarring and, rarely, to carcinogenesis. The occurrence of malignancies secondary to radiation therapy has become well known. While it is true that many genetic factors predispose some patients to second cancers, radiation also contributes to the increased relative risk.

TABLE 2

Potential Side Effects of Radiation Therapy

Site Early effects Late effects

Bone

Arrest of growth, pain, fracture

Bone marrow

Pancytopenia

Pancytopenia

Central nervous system/spinal cord

Headache, nausea, seizures, stroke

Lhermitte's sign,* paralysis, seizures, coma

Ear

Otitis, desquamation, hypoacusis, tinnitus

Eye

Conjunctivitis, keratitis, iritis, blindness, glaucoma, ulceration

Cataract, corneal ulcer, glaucoma, blindness

Heart

Pericarditis, congestive heart failure

Pericarditis, coronary artery disease, congestive heart failure

Joints

Stiffness, fixation

Kidney

Renal failure, hypertension

Larynx

Hoarseness, edema, dyspnea

Edema, chondritis, necrosis

Liver

Necrosis, hepatic failure

Lower gastrointestinal tract

Diarrhea, obstruction, bleeding

Diarrhea, obstruction, bleeding, fistula, necrosis

Lung

Cough, dyspnea, pneumonitis

Fibrosis, pneumonitis

Mucous membrane

Mucositis, ulceration

Atrophy, ulceration, telangiectasia

Pharynx/esophagus

Dysphagia, ulceration, obstruction, perforation, fistula

Dysphagia, fibrosis, necrosis, perforation

Salivary gland

Xerostomia, dysguesia

Xerostomia, dysguesia, fibrosis

Skin

Erythema, epilation, edema, desquamation, ulceration

Atrophy, telangiectasia, pigment changes, alopecia, ulceration

Soft tissue

Inflammation

Fibrosis, necrosis

Upper gastrointestinal tract

Anorexia, nausea, pain, obstruction, bleeding

Obstruction, fibrosis, fistula

Any area

Secondary malignancy: 1 in 1,000 at 10 years after treatment†


*—Electric-shock–like sensation felt when the head is flexed.

†—Approximation.

Adapted with permission from Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [Editorial]. Int J Radiat Oncol Biol Phys 1995;31:1341–6.

TABLE 2   Potential Side Effects of Radiation Therapy

View Table

TABLE 2

Potential Side Effects of Radiation Therapy

Site Early effects Late effects

Bone

Arrest of growth, pain, fracture

Bone marrow

Pancytopenia

Pancytopenia

Central nervous system/spinal cord

Headache, nausea, seizures, stroke

Lhermitte's sign,* paralysis, seizures, coma

Ear

Otitis, desquamation, hypoacusis, tinnitus

Eye

Conjunctivitis, keratitis, iritis, blindness, glaucoma, ulceration

Cataract, corneal ulcer, glaucoma, blindness

Heart

Pericarditis, congestive heart failure

Pericarditis, coronary artery disease, congestive heart failure

Joints

Stiffness, fixation

Kidney

Renal failure, hypertension

Larynx

Hoarseness, edema, dyspnea

Edema, chondritis, necrosis

Liver

Necrosis, hepatic failure

Lower gastrointestinal tract

Diarrhea, obstruction, bleeding

Diarrhea, obstruction, bleeding, fistula, necrosis

Lung

Cough, dyspnea, pneumonitis

Fibrosis, pneumonitis

Mucous membrane

Mucositis, ulceration

Atrophy, ulceration, telangiectasia

Pharynx/esophagus

Dysphagia, ulceration, obstruction, perforation, fistula

Dysphagia, fibrosis, necrosis, perforation

Salivary gland

Xerostomia, dysguesia

Xerostomia, dysguesia, fibrosis

Skin

Erythema, epilation, edema, desquamation, ulceration

Atrophy, telangiectasia, pigment changes, alopecia, ulceration

Soft tissue

Inflammation

Fibrosis, necrosis

Upper gastrointestinal tract

Anorexia, nausea, pain, obstruction, bleeding

Obstruction, fibrosis, fistula

Any area

Secondary malignancy: 1 in 1,000 at 10 years after treatment†


*—Electric-shock–like sensation felt when the head is flexed.

†—Approximation.

Adapted with permission from Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [Editorial]. Int J Radiat Oncol Biol Phys 1995;31:1341–6.

Specific Cancers

Radiation therapy has many potential specific indications. It can be given as primary tumor treatment, as pre- or postoperative therapy, or as a component of combination or consolidative therapy (Table 3). Radiotherapy will benefit patients with many different types of cancer. The following discussion highlights some specific potential uses of radiation therapy.

TABLE 3

Potential Roles of Radiotherapy

Radiation therapy as optimal primary treatment

Anal and perianal cancer

Certain Hodgkin's and non-Hodgkin's lymphomas

Early laryngeal cancer

Nasopharyngeal cancer

Nonmelanoma skin cancers in certain sites

Unresectable lung cancer

Radiation therapy as optional primary treatment

Bladder cancer

Esophageal cancer

Early head and neck cancer

Advanced lung cancer

Prostate cancer

Uterine cervical cancer

Preoperative radiation therapy useful

Certain advanced breast cancers

Certain advanced lung cancers

Certain advanced rectal cancers

Certain sarcomas

Postoperative radiation therapy useful

Breast conservation in early stage

Breast-chest wall and lymphatics in advanced stage

Endometrial cancer

Gastric cancer

Gliomas

Advanced head and neck cancer

Pancreatic cancer

Certain advanced rectal cancers

Testicular seminoma

Consolidative radiation therapy after chemotherapy

Hodgkin's lymphoma

Non-Hodgkin's lymphoma

TABLE 3   Potential Roles of Radiotherapy

View Table

TABLE 3

Potential Roles of Radiotherapy

Radiation therapy as optimal primary treatment

Anal and perianal cancer

Certain Hodgkin's and non-Hodgkin's lymphomas

Early laryngeal cancer

Nasopharyngeal cancer

Nonmelanoma skin cancers in certain sites

Unresectable lung cancer

Radiation therapy as optional primary treatment

Bladder cancer

Esophageal cancer

Early head and neck cancer

Advanced lung cancer

Prostate cancer

Uterine cervical cancer

Preoperative radiation therapy useful

Certain advanced breast cancers

Certain advanced lung cancers

Certain advanced rectal cancers

Certain sarcomas

Postoperative radiation therapy useful

Breast conservation in early stage

Breast-chest wall and lymphatics in advanced stage

Endometrial cancer

Gastric cancer

Gliomas

Advanced head and neck cancer

Pancreatic cancer

Certain advanced rectal cancers

Testicular seminoma

Consolidative radiation therapy after chemotherapy

Hodgkin's lymphoma

Non-Hodgkin's lymphoma

HEAD AND NECK CANCER

In patients with cancer of the head and neck, radiation can be used as primary therapy or as postoperative treatment. Sometimes radiation is given in combination with chemotherapy. One of the most beneficial results of radiotherapy is laryngeal preservation in persons with cancer of the vocal cord.4 Because of their location, nasopharyngeal cancers are treated primarily with radiation therapy. Many patients can be re-treated successfully should the tumor recur. Postoperatively, patients with large, extensively invasive tumors or tumors that have positive or close margins, and patients with positive lymph nodes are at high risk for local or regional recurrence. Radiation therapy increases the chance of local control of these tumors and often improves survival in patients with tumors of the head and neck.5

SKIN CANCER

Skin cancer can be treated primarily or postoperatively with radiation. Generally, primary treatment is reserved for use in areas where the cosmetic result with surgery may not be suitable. Most commonly, these include areas around the nose, ear, upper lip and commissure, eyelid and canthi. Similarly, postoperative irradiation increases local control in high-risk patients.6

CENTRAL NERVOUS SYSTEM TUMORS

Sometimes primary radiotherapy is indicated because the tumor location precludes surgery. But most commonly, postoperative radiation is employed. Radiation therapy improves survival in many patients with high-grade gliomas and in some patients with low-grade gliomas.7 New methods of conformal and stereotactic therapy, which more precisely focus the treatment beam using a three-dimensional technique, allow higher doses of radiation to be administered safely and accurately. These techniques seem particularly promising for the treatment of brain tumors.

GENITOURINARY CANCERS

In selected patients with invasive bladder cancer, radiation along with chemotherapy may help to preserve the bladder and its function.8 Prostate cancer can be treated primarily or postoperatively with radiation. It appears that, stage for stage, radical prostatectomy and primary radiotherapy offer the same chance of disease-free survival for prostate cancer patients.9 Recently, androgen blockade has been found to enhance local control and improve survival rates. Radiation therapy is associated with lower morbidity in patients with prostate cancer, particularly when conformal therapy or radioactive seed implants are used. With radiation, it is often possible to avoid the occurrence of impotence and incontinence, which are more common with other therapies.

In patients who have had a prostatectomy and who have a high risk of local recurrence, such as those with tumors with positive margins or a rising level of prostate-specific antigen (PSA), radiation may improve local control and survival. Patients with early-stage testicular seminoma have a very high survival rate when treated with low-dose irradiation following radical orchiectomy.

GYNECOLOGIC TUMORS

Early stage (stage I) cervical cancer can be treated with radiotherapy as effectively as with surgery.10 Later (stages II and III) tumors are best treated with irradiation. Many cervical and endometrial cancers with unfavorable histologic characteristics are better controlled with postoperative radiation. Certain patients with ovarian cancer may benefit from intraperitoneal radioactive phosphorus given postoperatively. Vaginal and vulvar cancers are frequently treated with radiotherapy because the required surgery is often too extensive, and patients are often elderly.

BREAST CANCER

Radiation has dramatically altered the management of primary breast cancer. Two national consensus conferences have concluded that breast conservation, using lumpectomy and radiation therapy, is the treatment of choice in early-stage breast cancer.11 Cosmetic results are good in most patients, and survival is not compromised. Attempts are being made to identify patients at low risk who can be managed with lumpectomy alone, but so far, all groups of patients have better local control with added radiation. Many patients with locally advanced breast cancer show improvement in local control with radiotherapy, and recent trials have also shown increased survival following radiation.12,13

GASTROINTESTINAL TUMORS

Esophageal cancer is usually advanced by the time the patient seeks treatment. Radiotherapy, along with chemotherapy, appears to be as effective as surgery in most patients with esophageal cancer.14 In selected patients, preoperative chemoradiotherapy may offer the best results. Patients with stomach cancer also often present with advanced disease. Some studies suggest the best treatment in these patients is postoperative chemoradiotherapy if the tumor is resectable or chemoradiotherapy alone if it is unresectable.15 Similarly, postoperative chemoradiotherapy or chemoradiotherapy alone is the preferred treatment for resectable and unresectable pancreatic cancer.16

Certain high-risk patients with locally advanced colon cancer may have better local control and survival with adjuvant radiation therapy. Preoperative radiotherapy, often administered with chemotherapy, can down-stage advanced or low-lying rectal cancers and allow resection and preservation of the sphincter.17 In high-risk surgical patients, radiation therapy can be helpful postoperatively as well. Anal and perianal cancers are usually treated with combined radiation and chemotherapy because excellent results and sphincter preservation can be obtained.18

LUNG CANCER

Lung cancer should be treated surgically whenever possible. Postoperative radiation improves local control and may improve survival in certain high-risk surgical patients.19 Unresectable lung cancer can occasionally be made resectable with preoperative radiation. If resection is not possible, an approach combining radiation and chemotherapy is preferred.20 Administration of chemotherapy may precede or coincide with radiotherapy.

SARCOMAS

Wide local excision with preservation of function is indicated for soft tissue sarcomas. High-risk patients who receive preoperative or postoperative irradiation show improvement in local control and survival. By shrinking the tumor, preoperative radiation may allow more limited surgery and improvement in local control, which can also be limb sparing.21

LYMPHOMAS

Some patients with either non-Hodgkin's or Hodgkin's lymphoma may be best treated with radiotherapy. Many patients with low-grade non-Hodgkin's lymphoma can be treated with radiation alone, with excellent local control. Some patients with higher-grade non-Hodgkin's lymphoma with stage I or stage II disease have better survival with irradiation after chemotherapy.22 Hodgkin's lymphoma in selected patients with early-stage disease should be treated with radiation alone or combined with chemotherapy. Radiation therapy may also help control more advanced Hodgkin's lymphomas.

PEDIATRIC CANCERS

Pediatric cancer patients may benefit from radiation of central nervous system tumors (ependymomas, astrocytomas, medulloblastomas, embryonal tumors, brainstem gliomas, craniopharyngiomas, pineal tumors, cerebellar astrocytomas, optic gliomas, retinoblastomas, spinal cord tumors), neuroblastomas, lymphomas, Ewing's sarcoma, rhabdomyosarcomas and Wilm's tumor.

Palliative Care

In patients with metastatic cancer, radiation often improves quality of life and even survival (Table 4). Radiation is excellent for relief of painful bone metastases and may prevent pathologic fracture in weight-bearing bones. Generally, the pain relief afforded by radiation allows a reduction in pain medications and drug side effects. Spinal cord compression as a result of cancer is an emergency that can often be treated effectively with radiotherapy alone. Patients with back pain, weakness of the extremities, or problems with bowel or bladder control should be evaluated immediately to rule out cord compression. Superior vena cava syndrome, another potential emergency, usually responds well to radiotherapy. Patients usually present with dyspnea, orthopnea and venous congestion in the neck and upper extremities. Likewise, airway compression caused by cancer can often be treated effectively with radiotherapy. Short courses of radiation may improve median survival and quality of life in patients with brain metastases. If the only clinical disease is a single brain metastasis, the combined approaches of either surgery and whole-brain irradiation or stereotactic radiation and whole-brain irradiation improve the median survival rate most dramatically.23

TABLE 4

Important Cancer Syndromes in Which Radiation Therapy Is Palliative

Condition Symptoms Treatment

Painful bone metastasis

Bone pain

Analgesics, radiation treatments, hormonal/medical management, radiopharmaceuticals

Spinal cord compression

Back pain, especially radicular pain, neurologic deficits, bowel/bladder dysfunction

Steroids, then surgery and radiation or radiation alone

Superior vena cava syndrome

Dyspnea, orthopnea, venous congestion

Steroids, diuretics, oxygen, chemotherapy, radiation treatments

Brain metastasis

Headache, cognitive deficits, focal deficits

Multiple metastases: steroids, then whole-brain radiation treatments

Single metastasis: steroids, then surgery or stereotactic radiotherapy, and whole-brain radiation treatments

TABLE 4   Important Cancer Syndromes in Which Radiation Therapy Is Palliative

View Table

TABLE 4

Important Cancer Syndromes in Which Radiation Therapy Is Palliative

Condition Symptoms Treatment

Painful bone metastasis

Bone pain

Analgesics, radiation treatments, hormonal/medical management, radiopharmaceuticals

Spinal cord compression

Back pain, especially radicular pain, neurologic deficits, bowel/bladder dysfunction

Steroids, then surgery and radiation or radiation alone

Superior vena cava syndrome

Dyspnea, orthopnea, venous congestion

Steroids, diuretics, oxygen, chemotherapy, radiation treatments

Brain metastasis

Headache, cognitive deficits, focal deficits

Multiple metastases: steroids, then whole-brain radiation treatments

Single metastasis: steroids, then surgery or stereotactic radiotherapy, and whole-brain radiation treatments

Benign Disease

Radiotherapy can be used to treat certain benign diseases (Table 5). Local strontium application can help prevent the local recurrence of a surgically resected eye pterygium. Superficial low-dose radiation treatment can help prevent local recurrence of surgically resected keloids. Radiation therapy is often used to treat pituitary adenomas successfully with minimal morbidity. Low-dose irradiation can sometimes improve Graves' ophthalmopathy in selected patients in whom other types of therapy have failed. Likewise, keratoacanthomas that fail to respond to other treatment usually respond well to irradiation. Hemangiomas also respond well to low-dose radiation. Radiotherapy can help control high-risk desmoids and Peyronie's disease. In some postoperative orthopedic patients, low-dose radiation can prevent heterotopic bone formation. Finally, arteriovenous malformations of the central nervous system may be eliminated with stereotactic radiotherapy, if the malformations are not surgically accessible.24

TABLE 5

Benign Diseases in Which Radiation Therapy May Be Used

Ameloblastoma

Aneurysmal bone cyst

Angiofibroma

Arteriovenous malformation

Chemodectoma

Chordoma

Craniopharyngioma

Desmoid tumor

Graves' ophthalmopathy

Gynecomastia associated with hormonal management of prostate cancer

Hemangioma

Heterotopic bone formation

Hypersplenism

Keloid

Keratoacanthoma

Meningioma

Peyronie's disease

Pituitary adenoma

Pterygium

Total lymphoid irradiation for autoimmune disease or organ transplantation

Vascular restenosis prevention

TABLE 5   Benign Diseases in Which Radiation Therapy May Be Used

View Table

TABLE 5

Benign Diseases in Which Radiation Therapy May Be Used

Ameloblastoma

Aneurysmal bone cyst

Angiofibroma

Arteriovenous malformation

Chemodectoma

Chordoma

Craniopharyngioma

Desmoid tumor

Graves' ophthalmopathy

Gynecomastia associated with hormonal management of prostate cancer

Hemangioma

Heterotopic bone formation

Hypersplenism

Keloid

Keratoacanthoma

Meningioma

Peyronie's disease

Pituitary adenoma

Pterygium

Total lymphoid irradiation for autoimmune disease or organ transplantation

Vascular restenosis prevention

The Author

BERNARD A. TISDALE, M.D., is medical director of the Radiation Oncology Center at Chippenham Medical Center and Johnston-Willis Hospitals, Inc., in Richmond, Va. Dr. Tisdale earned a medical degree and completed a residency in family practice at the University of Virginia School of Medicine, Charlottesville. He also completed a residency in radiation oncology at the University of Louisville School of Medicine in Kentucky.

Address correspondence to Bernard A. Tisdale, M.D., Radiation Oncology Center, Johnston-Willis Hospitals, 1401 Johnston-Willis Dr., Richmond, VA, 23235. Reprints are not available from the author.

REFERENCES

1. Cancer facts and figures—1997. Atlanta: American Cancer Society, 1997.

2. Perez C, Brady L, eds. Principles and practice of radiation oncology. 3d ed. Philadelphia: Lippincott-Raven, 1998.

3. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [Editorial]. Int J Radiat Oncol Biol Phys. 1995;31:1341–6.

4. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–90.

5. Ang KK, Garden AS. Post-operative radiation therapy for advanced head and neck cancers. ASTRO Course 503. Retrieved March 1998 from the World Wide Web: http://www.astro.org/members/meetings/oct97/courses.html.

6. Mendenhall WM, Parsons JT, Mendenhall NP, Brant TA, Stringer SP, Cassisi N, et al. Carcinoma of the skin of the head and neck with perineural invasion. Head Neck. 1989;11:301–8.

7. Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O'Fallon JR, Earle JD, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg. 1989;70:853–61.

8. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85–12. Int J Radiat Oncol Biol Phys. 1993;25:783–90.

9. Hanks GE. Treatment of early stage prostate cancer: radiotherapy. Important Adv Oncol. 1994:225–39.

10. Eifel PJ. Carcinoma of the cervix. ASTRO Course 213. Retrieved March 1998 from the World Wide Web:http://www.astro.org/members/meetings/oct97/courses.html.

11. National Institutes of Health Consensus Conference on Cervical Cancer. Proceedings of a conference held at the National Institutes of Health, Bethesda, Md., April 1–3,1996. DHHS publication no. (NIH) 96-4152.

12. Overgaard M, Hansen PS, Overgaard J, Rose C, Anderson M, Bach F, et al. Postoperative radiotherapy in high risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–55.

13. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–62.

14. American Society of Clinical Oncology. Program/proceedings of the American Society of Clinical Oncology:twenty-sixth annual meeting. Washington: The Society, 1990:105.

15. Rich T. Upper abdominal malignancies. ASTRO Course 109. Retrieved March 1998 from the World Wide Web: http://www.astro.org/members/meetings/oct97/courses.html.

16. Tisdale BA, Paris KJ, Lindberg RD, Jose B, Spanos W Jr. Radiation therapy for pancreatic cancer: a retrospective study of the University of Louisville experience. South Med J. 1995;88:741–4.

17. Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol. 1992;10:79–84.

18. American Society of Clinical Oncology. Program/proceedings. Washington: The Society, 1991:191.

19. Effects of post-operative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med. 1986;315:1377–81.

20. Sause W, Scott C, Taylor S, Johnson D, Livingston R, Komacki R, eds., et al. Preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer. RTOG 8808 ECOG 4588. Proceedings of the American Society of Clinical Oncology: thirtieth annual meeting, Dallas; May 14–17, 1994.

21. Barkley HT Jr, Martin RG, Romsdahl MM, Lindberg R, Zagars GK. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Radiat Oncol Biol Phys. 1988;14:693–9.

22. Glick J, Kim K, O'Connell M. An ECOG randomized phase III trial of CHOP versus CHOP + radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma. Proceedings of the ASCO meeting, 1995.

23. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.

24. Kondziolka D, Lundford L, Flizkinger J. Gamma knife stereotactic radiosurgery for cerebral vascular malformations. In: Stereotactic radiosurgery. New York: McGraw-Hill, 1993:136–46.


Copyright © 1999 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article